文章摘要
王磊，邢国平，王安宁，汪明玉，李昀，付文玉，钟池.恩他卡朋对异动症大鼠行为学及其纹状体区 DARPP-32 磷酸化表达的影响[J].神经损伤功能重建,2018,13(12):599-602
恩他卡朋对异动症大鼠行为学及其纹状体区 DARPP-32 磷酸化表达的影响
Effects of Entacapone on Behavior and DARPP-32 Phosphorylation in Striatum of Rats withLevodopa-Induced Dyskinesia
  
DOI：
中文关键词: 帕金森病  异动症  持续性多巴胺能刺激  恩他卡朋  环磷腺苷调节的磷酸化蛋白-32
英文关键词: Parkinson’s disease  dyskinesia  continuous dopaminergic stimulation  entacapone  DARPP-32
基金项目:山东省医药卫生科技发展计划项目（No. 2014WS0266）
作者单位
王磊1，邢国平1，王安宁1，汪明玉1，李昀1，付文玉2，钟池1 1.潍坊市人民医院神经内科；2.潍坊医学院组织学与胚胎学教研室 
摘要点击次数: 3484
全文下载次数: 3753
中文摘要:
      目的：通过观察肢体缺血后处理（LIP）后p-Akt、Caspase-9 及Bcl-2 蛋白的表达，探讨PI3K/PKB信号途 径在远程LIP 减轻脑缺血再灌注损伤中的作用。方法：42 只大鼠随机分成对照组、缺血再灌注（IR）组和LIP 组各14 只，后2 组采用线栓法制备局灶性脑缺血再灌注模型，LIP 组在缺血2 h 后再灌注前实施3 个循环健 侧股动脉缺血5 min再灌注5 min的LIP。采用TTC染色测定脑梗死体积，免疫组化法检测p-Akt、Caspase-9、 Bcl-2蛋白的表达。结果：LIP组大鼠脑梗死体积较IR组明显减小（P＜0.05）。LIP组p-Akt、Bcl-2蛋白表达较 IR 组明显增高（P＜0.05），LIP 组Caspase-9 蛋白表达较IR 组明显降低（P＜0.05）。结论：LIP 可上调p-Akt、 Bcl-2表达，下调Caspase-9表达，并减轻脑梗死体积，PI3K/PKB信号通路在LIP减轻脑缺血再灌注损伤中可能 发挥重要保护作用。
英文摘要:
      To study the behavioral characteristics and changes in DARPP-32 phosphorylation level in the striatum of the levodopa/carbidopa and levodopa/carbidopa/entacapone-induced dyskinesia rat model. Methods: Twenty-nine Parkinson’s disease rat models were successfully established then randomly divided into four groups. The normal saline (NS) group included 5 rats, and the levodopa/carbidopa (LC) group, entacapone equivalent dose (LCE) group, and entacapone additional dose (LCE+) group each included 8 rats. Rats in each group were given intragastric administrations of the corresponding drugs for 28 days. Rat behavior was observed on the 1st, 4th, 8th, 12th, 16th, 20th, 24th, and 27th day after drug administration. Changes in DARPP-32 phosphorylation level in the striatum were measured by western blot technique. Results: The abnormal involuntary movement (AIM) scores of the LCE group and LC group were respectively (21.7±10.2) and (22.2± 11.1) points, the difference showing no statistical significance (P>0.05), and the difference between the AIM scores of the two groups at each measured timepoint showed no statistical significance (P>0.05). The AIM score of the LCE+ group was (28.6±14.9) points, and this was higher than that of the LCE group and LC group (both P<0.05). Starting with the 8th day of drug administration, the AIM score of the LCE+ group began surpassing that of the LC group and LCE group (both P<0.05). The LCE, LCE+, and LC groups showed a higher lesion-side DARPP-32 phosphorylation level than that of the non-lesion side of all groups (all P<0.05). The LCE+ group showed a higher lesion-side DARPP-32 phosphorylation level than that of the NS, LCE, and LC groups (P< 0.05). The LCE group and LC group lesion-side DARPP-32 phosphorylation levels displayed no significant difference (P>0.05). Conclusion: The addition of entacapone to levodopa treatment under equivalent dose conditions results in neither deterioration nor relief of dyskinesia.
查看全文   查看/发表评论  下载PDF阅读器
关闭